Literature DB >> 8194224

Survival of the Lubinus hip prosthesis. An eight- to 12-year follow-up evaluation of 444 cases.

E Partio1, H von Bonsdorff, J Wirta, V Avikainen.   

Abstract

The Kaplan-Meier survival method was used to analyze 444 Lubinus arthroplasties in 398 patients who were observed between eight and 12 years. The indication for arthroplasty was osteoarthrosis in 316 hips, rheumatoid arthritis in 84 hips, and various other conditions for the other 44 hips. Survival was determined for the entire prosthesis, as well as separately for the femoral stem, the acetabulum cup, and their four subgroups. Four patient-related variables (diagnosis, gender, age, and weight) were analyzed. The overall survival of the Lubinus implants was 97.1% at five years and 87.1% at ten years. No significant difference in survival was found between the acetabular and femoral components. Survival was not significantly better with a new anatomic (SP1) stem than with the old curved one (IP). Of the four patient-related variables studied, only diagnosis and age had a significant effect on prosthesis survival. There was no difference in survival between osteoarthrosis and rheumatoid arthrosis hips, but survival was clearly poorer at ten years in the miscellaneous diagnosis group. The authors obtained a significantly lower survival percentage for patients younger than 65 years of age than for those 65 years and older. There were no deep postoperative infections in this series. The revision rate was 11.5%. The wear seen at the lower front edge of cups that were removed is discussed.

Entities:  

Mesh:

Year:  1994        PMID: 8194224

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  1 in total

Review 1.  Early proximal migration of cups is associated with late revision in THA: a systematic review and meta-analysis of 26 RSA studies and 49 survivalstudies.

Authors:  Bart G Pijls; Marc J Nieuwenhuijse; Marta Fiocco; Josepha Wm Plevier; Saskia Middeldorp; Rob Ghh Nelissen; Edward R Valstar
Journal:  Acta Orthop       Date:  2012-11-05       Impact factor: 3.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.